Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health Context and Transition to Occupational Exposure

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad framework, discussions of bone health and osteoporosis management have historically emphasized the benefits of pharmacological treatments, including bisphosphonates such as Fosamax, in reducing fracture risk. This general health perspective typically focuses on patient education, treatment adherence, and the balance of risks and benefits in clinical settings. Transitioning from this general health context to a more specific occupational exposure concern requires a shift in focus. While the legacy theme addresses patient populations and clinical outcomes, the emerging concern centers on the potential for adverse effects in individuals who may encounter Fosamax not as prescribed therapy but through occupational pathways. This pivot acknowledges that exposure to pharmaceutical agents can occur in manufacturing, handling, or disposal environments, raising distinct questions about risk profiles outside the therapeutic context. The bridge concept thus moves from a patient-oriented, general health framework to an occupational exposure paradigm. In this new focus, the key question becomes whether and how workplace contact with Fosamax might be associated with osteonecrosis of the jaw, a condition previously linked to therapeutic use. This transition preserves the neutral academic tone by framing the inquiry as a logical extension of existing knowledge into a different exposure scenario, without invoking mechanistic claims or citing specific evidence.

Pharmacology and Recognized Adverse Effects of Fosamax

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, necrotic bone in the jaw that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ often involves pain, swelling, and non-healing extraction sockets. Diagnosis is typically based on clinical examination and imaging, with the hallmark being exposed bone in the oral cavity that persists for more than eight weeks.

Mechanistic Pathways and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding involves the drug's potent inhibition of osteoclast activity. Bisphosphonates like Fosamax suppress bone turnover, which can impair the jawbone's ability to remodel and repair microdamage. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique structure and physiology of the jawbone may make it particularly susceptible to the effects of bisphosphonate therapy. Risk factors for developing ONJ while taking Fosamax include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline, Population Data, and Causation Considerations

Regarding the timeline between exposure and documented harm, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Population-level data from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study underscores that while the absolute risk is low, the relative risk increases substantially with prolonged exposure. Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and the potential for increased risk with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label notes that the optimal duration of use has not been determined, and for patients at low risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, excluding other potential causes such as cancer or other medications. The label acknowledges that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that known risk factors include invasive dental procedures and concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The recurrence of symptoms upon rechallenge with the same or another bisphosphonate further supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative oral care, and avoidance of invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of developing osteonecrosis of the jaw from Fosamax?

The absolute risk of ONJ from Fosamax is low, approximately 0.05% after 5 years of use, but the relative risk increases with longer duration. A cohort study found a threefold higher risk after 2-3 years and an eightfold higher risk after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the warning signs of osteonecrosis of the jaw?

Warning signs include pain, swelling, and non-healing extraction sockets in the jaw. Diagnosis is based on clinical examination and imaging, with exposed bone persisting for more than eight weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.